The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TAS-115, a potent MET/VEGFRs-targeted kinase inhibitor with high tolerability, to suppress NSCLC-driven bone disruption.
 
Hidenori Fujita
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Akira Gomori
Employment - Taiho Pharmaceutical
 
Motomu Sakuragi
Employment - Taiho Pharmaceutical
 
Akihiro Hashimoto
Employment - Taiho Pharmaceutical
 
Kenjiro Ito
Employment - Taiho Pharmaceutical
 
Takamasa Suzuki
Employment - Taiho Pharmaceutical
 
Yayoi Fujioka
Employment - Taiho Pharmaceutical
 
Kazuhiko Yonekura
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Takekazu Aoyama
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka
 
Nobuaki Matsubara
Consulting or Advisory Role - AstraZeneca; Janssen
Speakers' Bureau - AstraZeneca; Chugai Pharma; Janssen; Pfizer; Sanofi; Taiho Pharmaceutical; Takeda
Research Funding - Bayer (Inst); Janssen (Inst); Shionogi (Inst)
 
Toshihiko Doi
Honoraria - Chugai Pharma; Novartis
Consulting or Advisory Role - Amgen; Lilly Japan; Merck Serono; Otsuka
Research Funding - Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Janssen (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); NanoCarrier; Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Zenyaku Kogyo (Inst)
 
Yoshikazu Iwasawa
Employment - Taiho Pharmaceutical
Stock and Other Ownership Interests - Otsuka